Critical

Peripheral intravenous noradrenaline administration

Vasopressor delivery · Shock / Sepsis
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Starting noradrenaline through a well-sited large peripheral cannula to avoid delaying vasopressor support while central access is obtained. Safe for short-term use with the right precautions; the main hazard is extravasation causing tissue necrosis.

Red flags

  • Site blanching, pain, swelling or coolness (early extravasation)
  • Escalating dose >0.5 mcg/kg/min via a peripheral line
  • Distal pulse loss or digital ischaemia
  • Cannula sited distally (hand/wrist/foot) or in a small vein
  • Infusion running >6 h without central access plan

Assessment

Differential diagnosis

  • Septic (distributive) shock
  • Anaphylactic shock
  • Post-induction / sedation-related vasoplegia
  • Cardiogenic shock requiring pressor support
  • Neurogenic shock

Investigations

  • Lactate and venous/arterial blood gas
  • Continuous invasive or frequent non-invasive BP monitoring
  • Bloods: FBC, U&E, CRP, cultures (if sepsis)
  • ECG and cardiac monitoring
  • Regular inspection of the cannula site for blanching/swelling

Management

  • Confirm shock and resuscitation target (MAP ≥65 mmHg) and that vasopressor is indicated now, not after central access
  • Site a reliable ≥18-20G cannula in a large proximal vein (antecubital fossa or forearm), avoiding wrist, hand and foot; test with a flush
  • Use diluted noradrenaline (e.g. 4 mg in 250 mL = 16 mcg/mL) via a volumetric pump with a dedicated lumen
  • Start low and titrate to MAP ≥65 mmHg; reassess perfusion and lactate
  • Inspect the site every 15-30 min and keep the limb visible; mark the vein
  • Arrange central venous access within 6-24 h (or sooner if dose rising or run prolonged)
  • If extravasation occurs, stop infusion, leave cannula, aspirate, and treat with phentolamine; escalate to central line
  • Document indication, concentration, site and duration

Drugs & doses

Noradrenaline (peripheral) — 4 mg in 250 mL 0.9% saline (16 mcg/mL) IV, 0.05-0.5 mcg/kg/min titrated to MAP ≥65 mmHg; limit to <72 h or until central access
Phentolamine — 5-10 mg in 10-15 mL 0.9% saline infiltrated subcutaneously around the extravasation site (antidote)
Glyceryl trinitrate 2% ointment — 1-2 cm topically to ischaemic/blanched skin as an alternative/adjunct for extravasation

Disposition

Admit to a critical care or high-dependency area with a clear plan for timely central venous access and ongoing site surveillance.

Complications & pitfalls

  • Extravasation causing skin and soft-tissue necrosis
  • Digital/limb ischaemia
  • Thrombophlebitis
  • Delayed recognition of line failure with recurrent hypotension
  • Compartment syndrome (large-volume extravasation)

Exam pearls

  • Peripheral noradrenaline for a few hours is safer than hypoperfusion while awaiting a central line
  • Proximal, large-vein, short-duration and vigilant monitoring are the key safety rules
  • Keep phentolamine and GTN ointment immediately available wherever peripheral vasopressors run
  • Most extravasation injuries occur with distal cannulae and concentrated preparations

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.